NCT01107093View on ClinicalTrials.gov

Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Contraception
Interventions
DRUG

CDB-2914 (ulipristal acetate)

single oral dose of 30 mg

DRUG

Placebo

single oral dose

Trial Locations (2)

Unknown

ICMER, Santiago

Clinica de PROFAMILIA, Santo Domingo

Sponsors

Lead Sponsor

HRA Pharma
All Listed Sponsors
lead

HRA Pharma

INDUSTRY

NCT01107093 - Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge | Biotech Hunter | Biotech Hunter